Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 03, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections
December 16, 2021 11:36 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 01, 2021 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
November 10, 2021 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare...
Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
November 08, 2021 16:05 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter -- BARDA Contract Expanded to Include sNDA Anthrax...
Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
November 01, 2021 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 01, 2021 16:04 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
October 18, 2021 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 01, 2021 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...